Wird geladen...
Zanubrutinib for the treatment of relapsed or refractory mantle cell lymphoma
Zanubrutinib, a highly selective Bruton tyrosine kinase inhibitor, was evaluated in a phase 1/2 study in patients with various B-cell malignancies. In the subgroup of patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL), zanubrutinib was administered as 160 mg twice daily (n = 14), 320...
Gespeichert in:
| Veröffentlicht in: | Blood Adv |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , |
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
American Society of Hematology
2021
|
| Schlagworte: | |
| Online Zugang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8270663/ https://ncbi.nlm.nih.gov/pubmed/34152395 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2020004074 |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|